Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
W-1 (Shenyang Pharma Univ.)
- Development stage
- Unknown
- Lead developer
- Shenyang Pharmaceutical University
01
Overview
W-1 (Shenyang Pharma Univ.): sourced facts only. name: "Our research group previously identified W-1, a key intermediate of Fexuprazan, as an inhibitor of CYP1B1 (IC50 = 0.16 μM)." [PMID:42401084]; target: "Our research group previously identified W-1, a key intermediate of Fexuprazan, as an inhibitor of CYP1B1 (IC50 = 0.16 μM)." [PMID:42401084]; developer: "Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China; Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China." [PMID:42401084]
02
Targets
CYP1B1 (Cytochrome P450 1B1)
Beyond the preview
Go deeper on W-1 (Shenyang Pharma Univ.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on W-1 (Shenyang Pharma Univ.).